Clinical Trials | November 14, 2025
Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Enabling a new era in minimally invasive obesity treatment across Europe
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
